CMV pneumonitis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
(Created page with "{{CMG}} {{CMV pneumonitis}} ==Overview== * Trials of ganciclovir with CMV IgG have not shown a consistent benefit in all studies. * Foscarnet is an alternative agent but data...") |
Esther Lee (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | |||
{{CMG}} | {{CMG}} | ||
{{CMV pneumonitis}} | {{CMV pneumonitis}} | ||
==Overview== | ==Overview== | ||
==Future or Investigational Therapies== | |||
* Trials of ganciclovir with CMV IgG have not shown a consistent benefit in all studies. | * Trials of ganciclovir with CMV IgG have not shown a consistent benefit in all studies. | ||
* Foscarnet is an alternative agent but data on its efficacy is lacking | * Foscarnet is an alternative agent but data on its efficacy is lacking | ||
Line 8: | Line 10: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Disease]] | |||
[[Category:Immunology]] | |||
[[Category:Pulmonology]] | |||
{{WH}} | |||
{{WS}} |
Latest revision as of 18:41, 25 September 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
CMV pneumonitis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
CMV pneumonitis future or investigational therapies On the Web |
American Roentgen Ray Society Images of CMV pneumonitis future or investigational therapies |
CMV pneumonitis future or investigational therapies in the news |
Blogs on CMV pneumonitis future or investigational therapies |
Risk calculators and risk factors for CMV pneumonitis future or investigational therapies |
Overview
Future or Investigational Therapies
- Trials of ganciclovir with CMV IgG have not shown a consistent benefit in all studies.
- Foscarnet is an alternative agent but data on its efficacy is lacking